{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T09:56:53Z","timestamp":1783850213773,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Emicizumab has improved prophylactic management of hemophilia A (HA), offering effective bleed prevention independent of factor VIII (FVIII) inhibitor status. However, prospective real-world pediatric data from low- and middle-income settings remain limited. We conducted a prospective cohort study of 72 children (&lt;\u200918\u00a0years) with HA receiving subcutaneous emicizumab prophylaxis for 12\u00a0months. The cohort comprised 70 patients with severe HA and 2 with moderate HA with severe bleeding phenotype. Patients included both inhibitor-positive and inhibitor-negative children. Outcomes included annualized bleeding rate (ABR), joint health assessed by Hemophilia Joint Health Score version 2.1 (HJHS 2.1), and functional capacity measured by the Functional Independence Score in Hemophilia (FISH). The. median ABR decreased from 40 (IQR 36\u201348) at baseline to 0 (IQR 0\u20130) after 12\u00a0months (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), with 79.16% of children experiencing zero treated bleeds. AJBR was 0 in 86.1% of patients, and all target joints resolved by 12\u00a0months. The median HJHS improved from 15 (IQR 7\u201322) to 9 (IQR 3\u201314) (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), and mean FISH score increased from 20.65\u2009\u00b1\u20094.25 to 26.02\u2009\u00b1\u20093.57 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), with greatest improvements in squatting, running, and stair climbing. Reductions in ABR, HJHS, and FISH were comparable between inhibitor-positive and inhibitor-negative patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusion<\/jats:italic>\n                    :\u00a0Emicizumab prophylaxis provides profound bleed control and meaningful improvements in joint and functional outcomes in children with HA, regardless of inhibitor status, supporting its use as standard pediatric prophylaxis in routine clinical practice.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td align=\"left\" colspan=\"2\">\n                              <jats:bold>What is Known:<\/jats:bold>\n                              \u2022\u00a0\n                              <jats:italic>Emicizumab effectively reduces bleeding in children with hemophilia A.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>Prospective real-world pediatric data in low- and middle-income settings remain limited.<\/jats:italic>\n                              <jats:bold>What is New:<\/jats:bold>\n                              \u2022\u00a0\n                              <jats:italic>This study showed near-complete bleed control, full target joint resolution.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>Comparable benefits were observed in children with and without inhibitors in a prospective real-world setting.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s00431-026-06872-z","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:20:10Z","timestamp":1775888410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors"],"prefix":"10.1007","volume":"185","author":[{"given":"Laila M.","family":"Sherief","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Elagamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada K.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Rashad","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Nazim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sobhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"6872_CR1","doi-asserted-by":"publisher","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al (2013) Guidelines for the management of hemophilia. Haemophilia 19:. https:\/\/doi.org\/10.1111\/J.1365-2516.2012.02909.X","DOI":"10.1111\/J.1365-2516.2012.02909.X"},{"key":"6872_CR2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/HAE.12300","volume":"20","author":"A Graham","year":"2014","unstructured":"Graham A, Jaworski K (2014) Pharmacokinetic analysis of anti-hemophilic factor in the obese patient. Haemophilia 20:226\u2013229. https:\/\/doi.org\/10.1111\/HAE.12300","journal-title":"Haemophilia"},{"key":"6872_CR3","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1056\/NEJMOA1516437","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Mannucci PM, Garagiola I et al (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 374:2054\u20132064. https:\/\/doi.org\/10.1056\/NEJMOA1516437","journal-title":"N Engl J Med"},{"key":"6872_CR4","doi-asserted-by":"publisher","unstructured":"Fischer K, Lewandowski D, Marijke van den Berg H, Janssen MP (2012) Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia 18:. https:\/\/doi.org\/10.1111\/J.1365-2516.2011.02687.X","DOI":"10.1111\/J.1365-2516.2011.02687.X"},{"key":"6872_CR5","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3324\/HAEMATOL.2022.282099","volume":"109","author":"PE Alcedo Andrade","year":"2024","unstructured":"Alcedo Andrade PE, Manucci PM, Kessler CM (2024) Emicizumab: the hemophilia A game-changer. Haematologica 109:1334\u20131347. https:\/\/doi.org\/10.3324\/HAEMATOL.2022.282099","journal-title":"Haematologica"},{"key":"6872_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/AJH.23957","volume":"90","author":"CE Walsh","year":"2015","unstructured":"Walsh CE, Soucie JM, Miller CH (2015) Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 90:400\u2013405. https:\/\/doi.org\/10.1002\/AJH.23957","journal-title":"Am J Hematol"},{"key":"6872_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/EJH.13108","volume":"101","author":"LS D\u2019Angiolella","year":"2018","unstructured":"D\u2019Angiolella LS, Cortesi PA, Rocino A et al (2018) The socioeconomic burden of patients affected by hemophilia with inhibitors. Eur J Haematol 101:435\u2013456. https:\/\/doi.org\/10.1111\/EJH.13108","journal-title":"Eur J Haematol"},{"key":"6872_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMOA067659","volume":"357","author":"MJ Manco-Johnson","year":"2007","unstructured":"Manco-Johnson MJ, Abshire TC, Shapiro AD et al (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357:535\u2013544. https:\/\/doi.org\/10.1056\/NEJMOA067659","journal-title":"N Engl J Med"},{"key":"6872_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMOA1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B et al (2017) Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 377:809\u2013818. https:\/\/doi.org\/10.1056\/NEJMOA1703068","journal-title":"N Engl J Med"},{"key":"6872_CR10","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1182\/BLOOD-2017-08-801662","volume":"130","author":"PJ Lenting","year":"2017","unstructured":"Lenting PJ, Denis VC, Christophe OD (2017) Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood 130:2463\u20132468. https:\/\/doi.org\/10.1182\/BLOOD-2017-08-801662","journal-title":"Blood"},{"key":"6872_CR11","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","volume":"6","author":"SW Pipe","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M et al (2019) Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 6:e295\u2013e305. https:\/\/doi.org\/10.1016\/S2352-3026(19)30054-7","journal-title":"Lancet Haematol"},{"key":"6872_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMOA1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I et al (2018) Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 379:811\u2013822. https:\/\/doi.org\/10.1056\/NEJMOA1803550","journal-title":"N Engl J Med"},{"key":"6872_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670","author":"R Yang","year":"2022","unstructured":"Yang R, Wang S, Wang X et al (2022) Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: a randomized study (HAVEN 5). Res Pract Thromb Haemost. https:\/\/doi.org\/10.1002\/rth2.12670","journal-title":"Res Pract Thromb Haemost"},{"key":"6872_CR14","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/BLOOD.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young G, Liesner R, Chang T et al (2019) A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134:2127\u20132138. https:\/\/doi.org\/10.1182\/BLOOD.2019001869","journal-title":"Blood"},{"key":"6872_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/S40262-017-0616-3","volume":"57","author":"K Yoneyama","year":"2018","unstructured":"Yoneyama K, Schmitt C, Kotani N et al (2018) A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet 57:1123\u20131134. https:\/\/doi.org\/10.1007\/S40262-017-0616-3","journal-title":"Clin Pharmacokinet"},{"key":"6872_CR16","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1182\/BLOOD-2019-128083","volume":"134","author":"A Li","year":"2019","unstructured":"Li A, Goodfriend C, Sokol J, Kruse-Jarres R (2019) Patterns and predictors of emicizumab adherence in people with hemophilia. Blood 134:2178\u20132178. https:\/\/doi.org\/10.1182\/BLOOD-2019-128083","journal-title":"Blood"},{"key":"6872_CR17","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR et al (2014) Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 12:1935\u20131939. https:\/\/doi.org\/10.1111\/jth.12672","journal-title":"J Thromb Haemost"},{"key":"6872_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ACR.20353","volume":"63","author":"BM Feldman","year":"2011","unstructured":"Feldman BM, Funk SM, Bergstrom BM et al (2011) Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 63:223\u2013230. https:\/\/doi.org\/10.1002\/ACR.20353","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6872_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/J.1365-2516.2007.01508.X","volume":"13","author":"PM Poonnoose","year":"2007","unstructured":"Poonnoose PM, Thomas R, Keshava SN et al (2007) Psychometric analysis of the Functional Independence Score in Haemophilia (FISH). Haemophilia 13:620\u2013626. https:\/\/doi.org\/10.1111\/J.1365-2516.2007.01508.X","journal-title":"Haemophilia"},{"key":"6872_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/J.1365-2516.2005.01142.X","volume":"11","author":"PM Poonnoose","year":"2005","unstructured":"Poonnoose PM, Manigandan C, Thomas R et al (2005) Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia 11:598\u2013602. https:\/\/doi.org\/10.1111\/J.1365-2516.2005.01142.X","journal-title":"Haemophilia"},{"issue":"6","key":"6872_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/HAE.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A et al (2020) WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26(6):1\u2013158. https:\/\/doi.org\/10.1111\/HAE.14046","journal-title":"Haemophilia"},{"key":"6872_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/J.1365-2141.2008.07386.X","volume":"143","author":"NWD Jansen","year":"2008","unstructured":"Jansen NWD, Roosendaal G, Lafeber FPJG (2008) Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 143:632\u2013640. https:\/\/doi.org\/10.1111\/J.1365-2141.2008.07386.X","journal-title":"Br J Haematol"},{"key":"6872_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/MBC.0000000000000767","volume":"29","author":"A Seuser","year":"2018","unstructured":"Seuser A, Khayat CD, Negrier C et al (2018) Evaluation of early musculoskeletal disease in patients with haemophilia: results from an expert consensus. Blood Coagul Fibrinolysis 29:509\u2013520. https:\/\/doi.org\/10.1097\/MBC.0000000000000767","journal-title":"Blood Coagul Fibrinolysis"},{"key":"6872_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/HAE.13848","volume":"25","author":"M Shima","year":"2019","unstructured":"Shima M, Nogami K, Nagami S et al (2019) A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 25:979\u2013987. https:\/\/doi.org\/10.1111\/HAE.13848","journal-title":"Haemophilia"},{"key":"6872_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/BLOOD.V130.SUPPL_1.86.86","volume":"130","author":"V Jimenez-Yuste","year":"2017","unstructured":"Jimenez-Yuste V, Shima M, Fukutake K et al (2017) Emicizumab subcutaneous dosing every 4 weeks for the management of hemophilia A: preliminary data from the pharmacokinetic run-in cohort of a multicenter, open-label, phase 3 study (HAVEN 4). Blood 130:86\u201386. https:\/\/doi.org\/10.1182\/BLOOD.V130.SUPPL_1.86.86","journal-title":"Blood"},{"key":"6872_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/FPED.2022.992267","author":"G Liu","year":"2022","unstructured":"Liu G, Huang K, Li G et al (2022) Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China. Front Pediatr. https:\/\/doi.org\/10.3389\/FPED.2022.992267","journal-title":"Front Pediatr"},{"key":"6872_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/S12887-022-03546-1","author":"H Glonnegger","year":"2022","unstructured":"Glonnegger H, Andresen F, Kapp F et al (2022) Emicizumab in children: bleeding episodes and outcome before and after transition to emicizumab. BMC Pediatr. https:\/\/doi.org\/10.1186\/S12887-022-03546-1","journal-title":"BMC Pediatr"},{"key":"6872_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/S40262-021-01042-W","volume":"60","author":"AAMT Donners","year":"2021","unstructured":"Donners AAMT, Rademaker CMA, Bevers LAH et al (2021) Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review. Clin Pharmacokinet 60:1395\u20131406. https:\/\/doi.org\/10.1007\/S40262-021-01042-W","journal-title":"Clin Pharmacokinet"},{"key":"6872_CR29","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/HAE.15105","volume":"30","author":"K Kengkla","year":"2024","unstructured":"Kengkla K, Wilairat P, Natesirinilkul R et al (2024) Evaluating the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: a cost-effectiveness and budget impact analysis in Thailand\u2019s upper-middle income setting. Haemophilia 30:1288\u20131297. https:\/\/doi.org\/10.1111\/HAE.15105","journal-title":"Haemophilia"},{"key":"6872_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/HAE.14968","volume":"30","author":"PM Mannucci","year":"2024","unstructured":"Mannucci PM, Hermans C (2024) Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries. Haemophilia 30:575\u2013576. https:\/\/doi.org\/10.1111\/HAE.14968","journal-title":"Haemophilia"},{"key":"6872_CR31","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/HAE.14884","volume":"29","author":"AE Bowyer","year":"2023","unstructured":"Bowyer AE, Hickey K, Kitchen S, Ezban M (2023) A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays. Haemophilia 29:1633\u20131637. https:\/\/doi.org\/10.1111\/HAE.14884","journal-title":"Haemophilia"},{"key":"6872_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/BLOOD-2020-138958","volume":"136","author":"K Yamaguchi","year":"2020","unstructured":"Yamaguchi K, Soeda T, Sato M et al (2020) Pharmacology and pharmacokinetics of NXT007; emicizumab-based engineered Fixa\/Fx bispecific antibody with improved properties. Blood 136:19\u201319. https:\/\/doi.org\/10.1182\/BLOOD-2020-138958","journal-title":"Blood"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-06872-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-06872-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:02:34Z","timestamp":1780120954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-06872-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6872"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-06872-z","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Scientific Research Ethical Committee, Faculty of Medicine, Kafrelsheikh University (Approval No. MKSU 50\u20136-7).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the parents or legal guardians of all participating children prior to enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}